Comparison of Two Mitotane Starting Dose Regimens in Patients With Advanced Adrenocortical Carcinoma

Stefanie Hahner, Martin Fassnacht, Mitotane for adrenocortical carcinoma treatment. Current opinion in investigational drugs. ,vol. 6, pp. 386- 394 ,(2005)

L. Chouchana, C. Narjoz, P. Beaune, M.-A. Loriot, X. Roblin, Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease Alimentary Pharmacology & Therapeutics. ,vol. 35, pp. 15- 36 ,(2012) , 10.1111/J.1365-2036.2011.04905.X

Matthias Kroiss, Marcus Quinkler, Werner K. Lutz, Bruno Allolio, Martin Fassnacht, Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma Clinical Endocrinology. ,vol. 75, pp. 585- 591 ,(2011) , 10.1111/J.1365-2265.2011.04214.X

Martin Fassnacht, Massimo Terzolo, Bruno Allolio, Eric Baudin, Harm Haak, Alfredo Berruti, Staffan Welin, Carmen Schade-Brittinger, André Lacroix, Barbara Jarzab, Halfdan Sorbye, David J Torpy, Vinzenz Stepan, David E Schteingart, Wiebke Arlt, Matthias Kroiss, Sophie Leboulleux, Paola Sperone, Anders Sundin, Ilse Hermsen, Stefanie Hahner, Holger S Willenberg, Antoine Tabarin, Marcus Quinkler, Christelle De La Fouchardière, Martin Schlumberger, Franco Mantero, Dirk Weismann, Felix Beuschlein, Hans Gelderblom, Hanneke Wilmink, Monica Sender, Maureen Edgerly, Werner Kenn, Tito Fojo, Hans-Helge Müller, Britt Skogseid, None, Combination Chemotherapy in Advanced Adrenocortical Carcinoma The New England Journal of Medicine. ,vol. 366, pp. 2189- 2197 ,(2012) , 10.1056/NEJMOA1200966

Vasileios Chortis, Angela E. Taylor, Petra Schneider, Jeremy W. Tomlinson, Beverly A. Hughes, Donna M. O'Neil, Rossella Libé, Bruno Allolio, Xavier Bertagna, Jérôme Bertherat, Felix Beuschlein, Martin Fassnacht, Niki Karavitaki, Massimo Mannelli, Franco Mantero, Giuseppe Opocher, Emilio Porfiri, Marcus Quinkler, Mark Sherlock, Massimo Terzolo, Peter Nightingale, Cedric H. L. Shackleton, Paul M. Stewart, Stefanie Hahner, Wiebke Arlt, Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement The Journal of Clinical Endocrinology and Metabolism. ,vol. 98, pp. 161- 171 ,(2013) , 10.1210/JC.2012-2851

Massimo Terzolo, Anna Pia, Alfredo Berruti, Giangiacomo Osella, Anna Alı̀, Valentino Carbone, Elio Testa, Luigi Dogliotti, Alberto Angeli, Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. The Journal of Clinical Endocrinology and Metabolism. ,vol. 85, pp. 2234- 2238 ,(2000) , 10.1210/JCEM.85.6.6619

Clarice W. Oien, Cliff Hurd, Daria P. Vorojeikina, Steven F. Amold, Angelo C. Notides, Transcriptional activation of the human estrogen receptor by DDT isomers and metabolites in yeast and MCF-7 cells. Biochemical Pharmacology. ,vol. 53, pp. 1161- 1172 ,(1997) , 10.1016/S0006-2952(97)00097-X

Antonio D’Avolio, Silvia De Francia, Vittoria Basile, Jessica Cusato, Francesca De Martino, Elisa Pirro, Francesca Piccione, Arianna Ardito, Barbara Zaggia, Marco Volante, Giovanni Di Perri, Massimo Terzolo, Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenetics and Genomics. ,vol. 23, pp. 293- 300 ,(2013) , 10.1097/FPC.0B013E3283606CB2

Saskia Houterman, Jan den Hartigh, Sophie Leboulleux, Fulvia Daffara, Alfredo Berruti, Rita Chadarevian, Martin Schlumberger, Bruno Allolio, Harm R. Haak, Eric Baudin, Ilse G. Hermsen, Martin Fassnacht, Massimo Terzolo, Plasma Concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study The Journal of Clinical Endocrinology and Metabolism. ,vol. 96, pp. 1844- 1851 ,(2011) , 10.1210/JC.2010-2676

Anders Andersen, Anna A. Kasperlik-Zaluska, David J. Warren, Determination of mitotane (o,p-DDD) and its metabolites o,p-DDA and o,p-DDE in plasma by high-performance liquid chromatography. Therapeutic Drug Monitoring. ,vol. 21, pp. 355- 359 ,(1999) , 10.1097/00007691-199906000-00020